What is the medical term for fatty liver disease, also known as Steatosis (Steatohepatitis)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The medical term for fatty liver is Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which replaces the old term non-alcoholic fatty liver disease (NAFLD) and encompasses various conditions including isolated liver steatosis, metabolic dysfunction-associated steatohepatitis (MASH), and fibrosis. This condition occurs when fat accumulates in liver cells, making up more than 5-10% of the liver's weight, and is tightly linked to type 2 diabetes, obesity, and other cardiometabolic risk factors 1. MASLD is associated with an increased risk of cardiovascular events, chronic kidney disease, hepatic and extrahepatic malignancies, and liver-related outcomes, including liver failure and hepatocellular carcinoma (HCC) 1.

The diagnosis of MASLD involves case-finding strategies using non-invasive tests, such as blood-based scores (e.g., FIB-4) and imaging techniques (e.g., transient elastography), particularly in individuals with cardiometabolic risk factors, abnormal liver enzymes, and/or radiological signs of hepatic steatosis 1. Treatment typically involves lifestyle modifications, including weight loss, dietary changes, physical exercise, and discouraging alcohol consumption, as well as optimal management of comorbidities, such as type 2 diabetes or obesity, using incretin-based therapies (e.g., semaglutide, tirzepatide) if indicated 1.

Some key points to consider in the management of MASLD include:

  • The use of a stepwise approach to rule out advanced fibrosis, which is predictive of liver-related outcomes 1
  • The consideration of bariatric surgery as an option in individuals with MASLD and obesity 1
  • The potential use of MASH-targeted treatment with resmetirom in adults with non-cirrhotic MASH and significant liver fibrosis (stage ≥2) 1
  • The importance of surveillance for portal hypertension and HCC, as well as liver transplantation in decompensated cirrhosis, in the management of MASH-related cirrhosis 1

From the Research

Fatty Liver Medical Term

The medical term for fatty liver is hepatic steatosis. This condition is characterized by the accumulation of excess fat in the liver cells, which can lead to liver damage and other health problems.

Definition and Prevalence

  • Hepatic steatosis is defined as intrahepatic fat of at least 5% of liver weight 2.
  • It is estimated to afflict 30% of the US population and over 75% of patients with Type 2 diabetes 3.
  • Steatotic liver disease, which encompasses hepatic steatosis, affects around 30% of the global population and is mainly driven by obesity, type 2 diabetes, and alcohol intake 4.

Associated Conditions

  • Hepatic steatosis is associated with obesity, type 2 diabetes, and dyslipidemia 2.
  • It is also linked to an increased risk of cardiovascular disease and liver-related mortality 3, 4.
  • Nonalcoholic fatty liver disease (NAFLD), which includes hepatic steatosis, is characterized by excessive deposition of fat in the liver and develops when hepatic fatty acid availability exceeds hepatic fatty acid disposal 5.

Pathophysiology

  • The pathophysiology of hepatic steatosis involves an imbalance between complex pathways of lipid metabolism, leading to an accumulation of fat in the liver 5.
  • Insulin resistance and oxidative stress are key factors in the development of hepatic steatosis and its progression to more severe forms of liver disease 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pathogenesis and Prevention of Hepatic Steatosis.

Gastroenterology & hepatology, 2015

Research

Steatotic liver disease.

Lancet (London, England), 2024

Research

Diabetes mellitus, obesity, and hepatic steatosis.

Seminars in gastrointestinal disease, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.